Showing 2,662 results

Filters Content type: News, Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

New & experimental hepatitis C treatment

Telaprevir May Cause Severe Cutaneous Eruptions

Editor's pick
Medscape (requires free registration)
24 April 2012
New & experimental hepatitis C treatment

Abbott interferon-free HCV combinations show early promise in untreated patients

News
23 April 2012
New & experimental hepatitis C treatment

Grading Hep C Stocks Exiting EASL - The future of hepatitis C therapy belongs to interferon-free regimens

Editor's pick
The Street
23 April 2012
New & experimental hepatitis C treatment

Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy

News
23 April 2012
New & experimental hepatitis C treatment

Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C

Editor's pick
Achillion (press release)
23 April 2012
New & experimental hepatitis C treatment

Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C

Editor's pick
Achillion (press release)
23 April 2012
New & experimental hepatitis C treatment

Adding TMC435 boosts response for difficult-to-treat hepatitis C patients

News
23 April 2012
New & experimental hepatitis C treatment

Hepatitis C drug alisporivir is effective, but pancreatitis a concern

News
23 April 2012
Hepatitis C treatment side-effects

Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment

News
20 April 2012
New & experimental hepatitis C treatment

Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos

News
20 April 2012
New & experimental hepatitis C treatment

J&J Open to Expanding Hepatitis C Collaboration With Vertex

Editor's pick
HCV New Drugs Research
20 April 2012
New & experimental hepatitis C treatment

Interferon-lambda as effective as alpha but with much better safety profile in hepatitis C

News
20 April 2012
New & experimental hepatitis C treatment

Pancreatitis Forces Halt to HCV Drug Trial

Editor's pick
MedPage Today
20 April 2012
New & experimental hepatitis C treatment

Janssen Creates new Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA

Editor's pick
Janssen press release
20 April 2012
New & experimental hepatitis C treatment

No Relevant Interactions Between Telaprevir and Two Newest Nonnucleosides Rilpivirine & Etravirine

Editor's pick
NATAP
20 April 2012
New & experimental hepatitis C treatment

Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naive Genotype 2 or 3 Hepatitis C Patients

Editor's pick
BMS press release
20 April 2012
New & experimental hepatitis C treatment

Gilead’s Experimental Hepatitis C Drug Cured 88% Post-Therapy

Editor's pick
Bloomberg
20 April 2012
New & experimental hepatitis C treatment

Boehringer Ingelheim Hepatitis C Drugs Cured 82% in Trial

Editor's pick
Bloomberg
20 April 2012
New & experimental hepatitis C treatment

Medivir Hep C Drug Cures 80% of Patients Post-Treatment

Editor's pick
Bloomberg BusinessWeek
20 April 2012
New & experimental hepatitis C treatment

Gilead, Bristol hepatitis C trial data impresses

Editor's pick
Reuters
20 April 2012
New & experimental hepatitis C treatment

Gilead, Bristol-Myers Squibb Put Profits Ahead of Best Care for Hep C Patients

Editor's pick
The Street
20 April 2012
New & experimental hepatitis C treatment

EASL-Anemia Management Strategies Used With VICTRELIS® (boceprevir) Combination Therapy

Editor's pick
HCV New Drugs Research
19 April 2012
New & experimental hepatitis C treatment

EASL-Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C-ABT-450/r, plus ABT-333 and ribavirin

Editor's pick
HCV New Drugs Research
19 April 2012
Hepatitis & HIV

Chronic hepatic diseases generate high costs to Europe

Editor's pick
Eurekalert Medicine & Health
19 April 2012